DENTSPLY SIRONA names CEO interim PFO as CFO exits Nov 5

DENTSPLY SIRONA (XRAY) announced a leadership change.

Rhea-AI Filing Summary

DENTSPLY SIRONA (XRAY) announced a leadership change. On October 31, 2025, the company determined that Matthew E. Garth will no longer serve as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun a search for its next CFO. The filing states Mr. Garth’s departure was not due to any disagreement regarding financial statements, internal controls, or operations.

Effective upon Mr. Garth’s departure, Daniel T. Scavilla, the company’s President and CEO and a director, was appointed as interim principal financial officer for SEC reporting. The company noted no new compensatory arrangements for Mr. Scavilla related to these additional responsibilities, and no related‑party relationships were disclosed.

Insights

Corporate governance analyst

CFO exits; CEO assumes interim finance role with continuity signals.

DENTSPLY SIRONA disclosed a CFO transition effective November 5, 2025, while appointing CEO Daniel T. Scavilla as interim principal financial officer for filings. This structure maintains reporting continuity during the search for a new CFO.

The company states the departure was not due to disagreements on financial statements, controls, or operations, which reduces concerns about accounting or control issues. No new compensation was entered into for the interim duties, suggesting a temporary bridge rather than a structural change.

Key items to watch are the timing and profile of the next CFO appointment as disclosed in subsequent filings, and any follow‑on amendment describing final arrangements related to the outgoing CFO.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did DENTSPLY SIRONA (XRAY) announce?

The company’s CFO, Matthew E. Garth, will leave the role effective November 5, 2025, and a search for a new CFO has begun.

Who will serve as interim principal financial officer at XRAY?

Daniel T. Scavilla, President and CEO, was appointed interim principal financial officer effective upon the CFO’s departure.

Did XRAY indicate any disagreements related to the CFO’s departure?

The filing states the departure was not due to any disagreement on financial statements, internal controls, or operations.

Will the interim appointment change compensation for XRAY’s CEO?

The company disclosed no new compensatory arrangements for Mr. Scavilla related to his interim principal financial officer role.

Will XRAY provide additional details on the CFO transition?

The company plans to file an amendment after finalizing arrangements related to Mr. Garth’s cessation of service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 08:14 AM Learn about SEC filing dates

0000818479false00008184792025-10-312025-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

October 31, 2025

Date of Report (Date of earliest event reported)

DENTSPLY SIRONA Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-16211

39-1434669

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

13320 Ballantyne Corporate Place,

Charlotte

North Carolina

28277-3607

(Address of principal executive offices)

(Zip Code)

(844) 848-0137

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			XRAY			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 31, 2025, DENTSPLY SIRONA Inc. (the “Company”) determined that Matthew E. Garth will no longer serve as the Executive Vice President and Chief Financial Officer of the Company effective November 5, 2025. The Company has initiated a search process to identify its next Chief Financial Officer. The Company will file an amendment to this Current Report on Form 8-K after any arrangements relating to Mr. Garth’s cessation of service have been finalized. Mr. Garth’s departure was not because of any disagreement with the Company on any matter relating to the Company’s financial statements, internal controls or operations, including accounting principles and practices.

Additionally, on November 5, 2025, the Company appointed Daniel T. Scavilla, the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, to the additional role of interim principal financial officer for purposes of the Company’s filings with the SEC, effective upon Mr. Garth’s departure.

For Mr. Scavilla’s biographical information, see the disclosure included under the heading “Appointment of Mr. Scavilla as President and Chief Executive Officer” of the Company’s Current Report on Form 8-K filed with the SEC on July 21, 2025, which disclosure is incorporated herein by reference.

Mr. Scavilla does not have any family relationship with any other director or executive officer of the Company, or person nominated or chosen by the Company to become a director or executive officer, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. No new compensatory arrangements will be entered into with Mr. Scavilla in connection with his assuming the responsibilities as the Company’s interim principal financial officer.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                         DENTSPLY SIRONA Inc.

By:						/s/ Daniel T. Scavilla
						Daniel T. Scavilla
						President and
						Chief Executive Officer

Date: November 6, 2025